Peanut Allergy: Starting Oral Immunotherapy After a Cafeteria Exposure
An 8-year-old's peanut allergy has been stable for years on avoidance alone — until a cafeteria exposure three months ago put him in an ambulance and reopened a question his family thought was settled.
Dario M., an 8-year-old boy, plays center-back for his rec-league soccer team and has spent the last three months refusing to eat lunch at school at all — not just avoiding peanut, but skipping the cafeteria entirely — ever since a shared table there put him in an ambulance in October. He has had IgE-mediated peanut allergy since a first hive-and-vomiting reaction at 14 months, and until October his family managed it the way most families do: label-reading, a school allergy plan on file, two epinephrine autoinjectors he had never actually needed. October's exposure was different. A classmate's sandwich touched his tray at a shared table, contact nobody saw coming, and within minutes he had lip swelling, hives across his trunk, and audible wheeze — one dose of intramuscular epinephrine from the school nurse, a second in the ambulance, before his oxygen saturation came back up. He has no asthma, no other food allergies, and is otherwise a healthy, active child whose allergy, until three months ago, had never put him anywhere near an ambulance.
His skin-prick wheal to peanut now measures 11mm and his peanut-specific IgE is 38 kU/L, both higher than at his last check — a trajectory that tracks with how close October actually came to being worse, not a coincidence of timing. PALISADE, the pivotal trial behind AR101 peanut oral immunotherapy, enrolled children ages 4 to 17 with confirmed peanut allergy and found 67.2% of treated children tolerated a 600mg peanut-protein challenge after a year of dosing, against 4% on placebo. Dario, at 8, with a recent unambiguous reaction and no exclusionary comorbidity, sits close to the center of that population, not its edge. The same trial's safety data are just as plain: gastrointestinal symptoms were the leading reason for discontinuation, and biopsy-confirmed eosinophilic esophagitis was identified in roughly 1% of the 1,217 participants treated across the AR101 development program — 0.27% within PALISADE itself — a low-frequency event, but one that would trade a food allergy for a second chronic diagnosis rather than resolve the first.
In clinic, three months after the cafeteria
I want to start oral immunotherapy, and I want to start it because of what October actually showed us, not despite it. Dario's peanut-specific IgE has climbed to 38 kU/L and his skin-prick wheal is now 11mm — both moving the wrong direction, both consistent with how close that exposure came to being worse. PALISADE enrolled children 4 to 17 with confirmed peanut allergy and found 67.2% of treated children tolerated a 600-milligram challenge after a year of AR101 dosing, against 4% on placebo. Dario isn't an edge case relative to that trial — he's close to its center: no asthma, no other food allergy, a documented reaction within the past year.
I'm not arguing October happened because his family did anything wrong — a sandwich on a shared table isn't a labeling failure. I'm arguing that a strategy whose entire protection depends on nobody else's food ever touching his doesn't have much margin left to lose.
I'm not disputing the population match or the desensitization numbers — PALISADE's benefit is real and it isn't being oversold here. What I want on the table before anyone signs a consent form is the other side of the same trial program: biopsy-confirmed eosinophilic esophagitis turned up in about 1 percent of the 1,217 patients treated across the AR101 studies — Chehade and colleagues' pooled safety analysis of the whole program — and it developed specifically in the group that started dosing, not as background incidence. That is a smaller number than the OIT literature at large reports, and I want to be accurate about that rather than argue from the highest figure available. EoE isn't a footnote — it's a chronic, symptomatic esophageal disease with its own elimination diet, its own endoscopic monitoring, and in a meaningful share of cases its own swallowed topical steroid. If it develops here, we haven't traded a peanut allergy for nothing; we've traded it for a second, ongoing diagnosis.
The 67 percent figure everyone quotes is calculated among children who completed a full year of dosing — the trial's own discontinuation data, driven mostly by GI symptoms, is part of the denominator this conversation keeps leaving out.
Both of those numbers matter, and I don't think either one is actually what's driving this family into my office. Dario has stopped eating lunch at school — not stopped eating peanut, stopped eating, period, at the place he spends six hours of every weekday, because he doesn't trust the room anymore. That's not a complication either trial measured, and it's happening now, regardless of which strategy we pick next. If OIT gets him back to a cafeteria table with a plan his family trusts, that's worth real weight even against a real EoE risk — and if it doesn't, avoidance with a far more concrete, rehearsed emergency plan than the one on file in October might close the same gap without the esophagus risk at all. I'd want Dario and his mother in that conversation, not deciding it for them.
Agreed, after two follow-up visits rather than one: OIT begins next month, on the allergist's proposed up-dosing schedule, with the gastroenterologist's explicit condition attached — any new dysphagia, food sticking, or reflux that doesn't resolve with routine measures within two weeks triggers endoscopy that same week, not at the next scheduled visit. The pediatrician's contribution wasn't a threshold at all; it was insisting Dario and his mother sit in on the actual decision rather than receive it, and both did.
Not agreed: how much of October's exposure the group should treat as evidence the avoidance strategy itself had failed, versus a single preventable lapse in one school's food-handling practice — the allergist reads it as the former, the gastroenterologist leans toward the latter, and Dario's mother, asked directly, said only that she didn't want to find out which reading was right by living through a second one.